Global Antifungal Agents

Antifungal Agents Comprehensive Study by Type (Echinocandins, Azoles, Ployenes, Allylamines, Others), Application (Powders, Ointments, Drugs, Pastes), Indications (Aspergillosis, Dermatophytosis, Candidiasis, Others) Players and Region - Global Market Outlook to 2028

Antifungal Agents Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Antifungal agents are the substances that inhibit the spread of fungi by killing fungal cells or spores or preventing their growth with minimal toxicity to the host. The mechanism of action of antifungals involves the inhibition of fungal membrane and cell wall synthesis, alternation of fungal membranes, effects on microtubules and inhibition of nucleic acid synthesis. The fungal infections include some kinds of dandruff, ringworm, vaginal infection, athlete’s foot and nail infection. They are primarily used to combat infections in immunocompromised individuals and post-transplantation

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledAbbott (United States), Pfizer Inc. (United States), Novartis AG (Switzerland), Merck & Co., Inc. (United States), Sanofi-Aventis (France), Bayer AG (Germany), Enzon Pharmaceuticals, Inc. (United States), GlaxoSmithKline Plc. (United Kingdom), Astellas Pharma (Japan) and Sigma-Aldrich (United States)


This growth is primarily driven by Rising Number of Patients Suffering From Fungal Infections, Decreased Immunity of the People Due To Busy Lifestyle Increases Susceptibility to Infection, Unhygienic Environment in the Cities with High Population and Availability Of Over the Counter Antifungal Drugs.

Globally, a noticeable market trend is evident Technological Progress in the Diagnostic Tests Major Players, such as Abbott (United States), Pfizer Inc. (United States), Novartis AG (Switzerland), Merck & Co., Inc. (United States), Sanofi-Aventis (France), Bayer AG (Germany), Enzon Pharmaceuticals, Inc. (United States), GlaxoSmithKline Plc. (United Kingdom), Astellas Pharma (Japan) and Sigma-Aldrich (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. Antifungal Agents market is a fragmented market due to the presence of various players. Companies are focusing on developing innovative products and solutions to improve quality, enhances and promotes performance, along with try to incorporate latest technology. The companies are coming up with partnerships or agreements along with planning strategic activities such as partnerships, product launch, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge.

Key Developments in the Market:
On 3rd December 2018, GlaxoSmithKline Plc. Reaches agreement to acquire TESARO, an oncology-focused Biopharmaceutical Company.
In May 2021, Pfizer acquired Amplyx Pharmaceuticals. Amplyx Pharmaceuticals is novel antifungal called fosmanogepix developer. This acquisition helped company to expand its presence in antifungal agents market

Influencing Trend:
Technological Progress in the Diagnostic Tests

Market Growth Drivers:
Rising Number of Patients Suffering From Fungal Infections, Decreased Immunity of the People Due To Busy Lifestyle Increases Susceptibility to Infection, Unhygienic Environment in the Cities with High Population and Availability Of Over the Counter Antifungal Drugs

Challenges:
Increased Resistance to Antifungal Drugs and Stringent Government Regulations

Restraints:
Lack of Awareness about Fungal Infections and Adverse Effects of the Antifungal Drugs

Opportunities:
Improving Healthcare Infrastructures and Growing Healthcare Budgets of Developing Countries

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Antifungal Agents Market
- Analysis about New Entrants in Antifungal Agents Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Antifungal Agents Study Sheds Light on
— The Antifungal Agents Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Antifungal Agents industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Antifungal Agents industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Echinocandins
  • Azoles
  • Ployenes
  • Allylamines
  • Others
By Application
  • Powders
  • Ointments
  • Drugs
  • Pastes
By Indications
  • Aspergillosis
  • Dermatophytosis
  • Candidiasis
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Number of Patients Suffering From Fungal Infections
      • 3.2.2. Decreased Immunity of the People Due To Busy Lifestyle Increases Susceptibility to Infection
      • 3.2.3. Unhygienic Environment in the Cities with High Population
      • 3.2.4. Availability Of Over the Counter Antifungal Drugs
    • 3.3. Market Challenges
      • 3.3.1. Increased Resistance to Antifungal Drugs
      • 3.3.2. Stringent Government Regulations
    • 3.4. Market Trends
      • 3.4.1. Technological Progress in the Diagnostic Tests
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antifungal Agents, by Type, Application, Indications and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Antifungal Agents (Value)
      • 5.2.1. Global Antifungal Agents by: Type (Value)
        • 5.2.1.1. Echinocandins
        • 5.2.1.2. Azoles
        • 5.2.1.3. Ployenes
        • 5.2.1.4. Allylamines
        • 5.2.1.5. Others
      • 5.2.2. Global Antifungal Agents by: Application (Value)
        • 5.2.2.1. Powders
        • 5.2.2.2. Ointments
        • 5.2.2.3. Drugs
        • 5.2.2.4. Pastes
      • 5.2.3. Global Antifungal Agents by: Indications (Value)
        • 5.2.3.1. Aspergillosis
        • 5.2.3.2. Dermatophytosis
        • 5.2.3.3. Candidiasis
        • 5.2.3.4. Others
      • 5.2.4. Global Antifungal Agents Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Antifungal Agents (Volume)
      • 5.3.1. Global Antifungal Agents by: Type (Volume)
        • 5.3.1.1. Echinocandins
        • 5.3.1.2. Azoles
        • 5.3.1.3. Ployenes
        • 5.3.1.4. Allylamines
        • 5.3.1.5. Others
      • 5.3.2. Global Antifungal Agents by: Application (Volume)
        • 5.3.2.1. Powders
        • 5.3.2.2. Ointments
        • 5.3.2.3. Drugs
        • 5.3.2.4. Pastes
      • 5.3.3. Global Antifungal Agents by: Indications (Volume)
        • 5.3.3.1. Aspergillosis
        • 5.3.3.2. Dermatophytosis
        • 5.3.3.3. Candidiasis
        • 5.3.3.4. Others
      • 5.3.4. Global Antifungal Agents Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Antifungal Agents (Price)
      • 5.4.1. Global Antifungal Agents by: Type (Price)
  • 6. Antifungal Agents: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co., Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi-Aventis (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bayer AG (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Enzon Pharmaceuticals, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline Plc. (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Astellas Pharma (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sigma-Aldrich (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Antifungal Agents Sale, by Type, Application, Indications and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Antifungal Agents (Value)
      • 7.2.1. Global Antifungal Agents by: Type (Value)
        • 7.2.1.1. Echinocandins
        • 7.2.1.2. Azoles
        • 7.2.1.3. Ployenes
        • 7.2.1.4. Allylamines
        • 7.2.1.5. Others
      • 7.2.2. Global Antifungal Agents by: Application (Value)
        • 7.2.2.1. Powders
        • 7.2.2.2. Ointments
        • 7.2.2.3. Drugs
        • 7.2.2.4. Pastes
      • 7.2.3. Global Antifungal Agents by: Indications (Value)
        • 7.2.3.1. Aspergillosis
        • 7.2.3.2. Dermatophytosis
        • 7.2.3.3. Candidiasis
        • 7.2.3.4. Others
      • 7.2.4. Global Antifungal Agents Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Antifungal Agents (Volume)
      • 7.3.1. Global Antifungal Agents by: Type (Volume)
        • 7.3.1.1. Echinocandins
        • 7.3.1.2. Azoles
        • 7.3.1.3. Ployenes
        • 7.3.1.4. Allylamines
        • 7.3.1.5. Others
      • 7.3.2. Global Antifungal Agents by: Application (Volume)
        • 7.3.2.1. Powders
        • 7.3.2.2. Ointments
        • 7.3.2.3. Drugs
        • 7.3.2.4. Pastes
      • 7.3.3. Global Antifungal Agents by: Indications (Volume)
        • 7.3.3.1. Aspergillosis
        • 7.3.3.2. Dermatophytosis
        • 7.3.3.3. Candidiasis
        • 7.3.3.4. Others
      • 7.3.4. Global Antifungal Agents Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Antifungal Agents (Price)
      • 7.4.1. Global Antifungal Agents by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antifungal Agents: by Type(USD Million)
  • Table 2. Antifungal Agents Echinocandins , by Region USD Million (2017-2022)
  • Table 3. Antifungal Agents Azoles , by Region USD Million (2017-2022)
  • Table 4. Antifungal Agents Ployenes , by Region USD Million (2017-2022)
  • Table 5. Antifungal Agents Allylamines , by Region USD Million (2017-2022)
  • Table 6. Antifungal Agents Others , by Region USD Million (2017-2022)
  • Table 7. Antifungal Agents: by Application(USD Million)
  • Table 8. Antifungal Agents Powders , by Region USD Million (2017-2022)
  • Table 9. Antifungal Agents Ointments , by Region USD Million (2017-2022)
  • Table 10. Antifungal Agents Drugs , by Region USD Million (2017-2022)
  • Table 11. Antifungal Agents Pastes , by Region USD Million (2017-2022)
  • Table 12. Antifungal Agents: by Indications(USD Million)
  • Table 13. Antifungal Agents Aspergillosis , by Region USD Million (2017-2022)
  • Table 14. Antifungal Agents Dermatophytosis , by Region USD Million (2017-2022)
  • Table 15. Antifungal Agents Candidiasis , by Region USD Million (2017-2022)
  • Table 16. Antifungal Agents Others , by Region USD Million (2017-2022)
  • Table 17. South America Antifungal Agents, by Country USD Million (2017-2022)
  • Table 18. South America Antifungal Agents, by Type USD Million (2017-2022)
  • Table 19. South America Antifungal Agents, by Application USD Million (2017-2022)
  • Table 20. South America Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 21. Brazil Antifungal Agents, by Type USD Million (2017-2022)
  • Table 22. Brazil Antifungal Agents, by Application USD Million (2017-2022)
  • Table 23. Brazil Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 24. Argentina Antifungal Agents, by Type USD Million (2017-2022)
  • Table 25. Argentina Antifungal Agents, by Application USD Million (2017-2022)
  • Table 26. Argentina Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 27. Rest of South America Antifungal Agents, by Type USD Million (2017-2022)
  • Table 28. Rest of South America Antifungal Agents, by Application USD Million (2017-2022)
  • Table 29. Rest of South America Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 30. Asia Pacific Antifungal Agents, by Country USD Million (2017-2022)
  • Table 31. Asia Pacific Antifungal Agents, by Type USD Million (2017-2022)
  • Table 32. Asia Pacific Antifungal Agents, by Application USD Million (2017-2022)
  • Table 33. Asia Pacific Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 34. China Antifungal Agents, by Type USD Million (2017-2022)
  • Table 35. China Antifungal Agents, by Application USD Million (2017-2022)
  • Table 36. China Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 37. Japan Antifungal Agents, by Type USD Million (2017-2022)
  • Table 38. Japan Antifungal Agents, by Application USD Million (2017-2022)
  • Table 39. Japan Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 40. India Antifungal Agents, by Type USD Million (2017-2022)
  • Table 41. India Antifungal Agents, by Application USD Million (2017-2022)
  • Table 42. India Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 43. South Korea Antifungal Agents, by Type USD Million (2017-2022)
  • Table 44. South Korea Antifungal Agents, by Application USD Million (2017-2022)
  • Table 45. South Korea Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 46. Taiwan Antifungal Agents, by Type USD Million (2017-2022)
  • Table 47. Taiwan Antifungal Agents, by Application USD Million (2017-2022)
  • Table 48. Taiwan Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 49. Australia Antifungal Agents, by Type USD Million (2017-2022)
  • Table 50. Australia Antifungal Agents, by Application USD Million (2017-2022)
  • Table 51. Australia Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Antifungal Agents, by Type USD Million (2017-2022)
  • Table 53. Rest of Asia-Pacific Antifungal Agents, by Application USD Million (2017-2022)
  • Table 54. Rest of Asia-Pacific Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 55. Europe Antifungal Agents, by Country USD Million (2017-2022)
  • Table 56. Europe Antifungal Agents, by Type USD Million (2017-2022)
  • Table 57. Europe Antifungal Agents, by Application USD Million (2017-2022)
  • Table 58. Europe Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 59. Germany Antifungal Agents, by Type USD Million (2017-2022)
  • Table 60. Germany Antifungal Agents, by Application USD Million (2017-2022)
  • Table 61. Germany Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 62. France Antifungal Agents, by Type USD Million (2017-2022)
  • Table 63. France Antifungal Agents, by Application USD Million (2017-2022)
  • Table 64. France Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 65. Italy Antifungal Agents, by Type USD Million (2017-2022)
  • Table 66. Italy Antifungal Agents, by Application USD Million (2017-2022)
  • Table 67. Italy Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 68. United Kingdom Antifungal Agents, by Type USD Million (2017-2022)
  • Table 69. United Kingdom Antifungal Agents, by Application USD Million (2017-2022)
  • Table 70. United Kingdom Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 71. Netherlands Antifungal Agents, by Type USD Million (2017-2022)
  • Table 72. Netherlands Antifungal Agents, by Application USD Million (2017-2022)
  • Table 73. Netherlands Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 74. Rest of Europe Antifungal Agents, by Type USD Million (2017-2022)
  • Table 75. Rest of Europe Antifungal Agents, by Application USD Million (2017-2022)
  • Table 76. Rest of Europe Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 77. MEA Antifungal Agents, by Country USD Million (2017-2022)
  • Table 78. MEA Antifungal Agents, by Type USD Million (2017-2022)
  • Table 79. MEA Antifungal Agents, by Application USD Million (2017-2022)
  • Table 80. MEA Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 81. Middle East Antifungal Agents, by Type USD Million (2017-2022)
  • Table 82. Middle East Antifungal Agents, by Application USD Million (2017-2022)
  • Table 83. Middle East Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 84. Africa Antifungal Agents, by Type USD Million (2017-2022)
  • Table 85. Africa Antifungal Agents, by Application USD Million (2017-2022)
  • Table 86. Africa Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 87. North America Antifungal Agents, by Country USD Million (2017-2022)
  • Table 88. North America Antifungal Agents, by Type USD Million (2017-2022)
  • Table 89. North America Antifungal Agents, by Application USD Million (2017-2022)
  • Table 90. North America Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 91. United States Antifungal Agents, by Type USD Million (2017-2022)
  • Table 92. United States Antifungal Agents, by Application USD Million (2017-2022)
  • Table 93. United States Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 94. Canada Antifungal Agents, by Type USD Million (2017-2022)
  • Table 95. Canada Antifungal Agents, by Application USD Million (2017-2022)
  • Table 96. Canada Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 97. Mexico Antifungal Agents, by Type USD Million (2017-2022)
  • Table 98. Mexico Antifungal Agents, by Application USD Million (2017-2022)
  • Table 99. Mexico Antifungal Agents, by Indications USD Million (2017-2022)
  • Table 100. Antifungal Agents Sales: by Type(K Units)
  • Table 101. Antifungal Agents Sales Echinocandins , by Region K Units (2017-2022)
  • Table 102. Antifungal Agents Sales Azoles , by Region K Units (2017-2022)
  • Table 103. Antifungal Agents Sales Ployenes , by Region K Units (2017-2022)
  • Table 104. Antifungal Agents Sales Allylamines , by Region K Units (2017-2022)
  • Table 105. Antifungal Agents Sales Others , by Region K Units (2017-2022)
  • Table 106. Antifungal Agents Sales: by Application(K Units)
  • Table 107. Antifungal Agents Sales Powders , by Region K Units (2017-2022)
  • Table 108. Antifungal Agents Sales Ointments , by Region K Units (2017-2022)
  • Table 109. Antifungal Agents Sales Drugs , by Region K Units (2017-2022)
  • Table 110. Antifungal Agents Sales Pastes , by Region K Units (2017-2022)
  • Table 111. Antifungal Agents Sales: by Indications(K Units)
  • Table 112. Antifungal Agents Sales Aspergillosis , by Region K Units (2017-2022)
  • Table 113. Antifungal Agents Sales Dermatophytosis , by Region K Units (2017-2022)
  • Table 114. Antifungal Agents Sales Candidiasis , by Region K Units (2017-2022)
  • Table 115. Antifungal Agents Sales Others , by Region K Units (2017-2022)
  • Table 116. South America Antifungal Agents Sales, by Country K Units (2017-2022)
  • Table 117. South America Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 118. South America Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 119. South America Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 120. Brazil Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 121. Brazil Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 122. Brazil Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 123. Argentina Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 124. Argentina Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 125. Argentina Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 126. Rest of South America Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 127. Rest of South America Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 128. Rest of South America Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 129. Asia Pacific Antifungal Agents Sales, by Country K Units (2017-2022)
  • Table 130. Asia Pacific Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 131. Asia Pacific Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 132. Asia Pacific Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 133. China Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 134. China Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 135. China Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 136. Japan Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 137. Japan Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 138. Japan Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 139. India Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 140. India Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 141. India Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 142. South Korea Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 143. South Korea Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 144. South Korea Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 145. Taiwan Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 146. Taiwan Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 147. Taiwan Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 148. Australia Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 149. Australia Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 150. Australia Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 151. Rest of Asia-Pacific Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 152. Rest of Asia-Pacific Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 153. Rest of Asia-Pacific Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 154. Europe Antifungal Agents Sales, by Country K Units (2017-2022)
  • Table 155. Europe Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 156. Europe Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 157. Europe Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 158. Germany Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 159. Germany Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 160. Germany Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 161. France Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 162. France Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 163. France Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 164. Italy Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 165. Italy Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 166. Italy Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 167. United Kingdom Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 168. United Kingdom Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 169. United Kingdom Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 170. Netherlands Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 171. Netherlands Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 172. Netherlands Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 173. Rest of Europe Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 174. Rest of Europe Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 175. Rest of Europe Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 176. MEA Antifungal Agents Sales, by Country K Units (2017-2022)
  • Table 177. MEA Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 178. MEA Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 179. MEA Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 180. Middle East Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 181. Middle East Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 182. Middle East Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 183. Africa Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 184. Africa Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 185. Africa Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 186. North America Antifungal Agents Sales, by Country K Units (2017-2022)
  • Table 187. North America Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 188. North America Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 189. North America Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 190. United States Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 191. United States Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 192. United States Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 193. Canada Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 194. Canada Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 195. Canada Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 196. Mexico Antifungal Agents Sales, by Type K Units (2017-2022)
  • Table 197. Mexico Antifungal Agents Sales, by Application K Units (2017-2022)
  • Table 198. Mexico Antifungal Agents Sales, by Indications K Units (2017-2022)
  • Table 199. Antifungal Agents: by Type(USD/Units)
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Company Basic Information, Sales Area and Its Competitors
  • Table 210. Antifungal Agents: by Type(USD Million)
  • Table 211. Antifungal Agents Echinocandins , by Region USD Million (2023-2028)
  • Table 212. Antifungal Agents Azoles , by Region USD Million (2023-2028)
  • Table 213. Antifungal Agents Ployenes , by Region USD Million (2023-2028)
  • Table 214. Antifungal Agents Allylamines , by Region USD Million (2023-2028)
  • Table 215. Antifungal Agents Others , by Region USD Million (2023-2028)
  • Table 216. Antifungal Agents: by Application(USD Million)
  • Table 217. Antifungal Agents Powders , by Region USD Million (2023-2028)
  • Table 218. Antifungal Agents Ointments , by Region USD Million (2023-2028)
  • Table 219. Antifungal Agents Drugs , by Region USD Million (2023-2028)
  • Table 220. Antifungal Agents Pastes , by Region USD Million (2023-2028)
  • Table 221. Antifungal Agents: by Indications(USD Million)
  • Table 222. Antifungal Agents Aspergillosis , by Region USD Million (2023-2028)
  • Table 223. Antifungal Agents Dermatophytosis , by Region USD Million (2023-2028)
  • Table 224. Antifungal Agents Candidiasis , by Region USD Million (2023-2028)
  • Table 225. Antifungal Agents Others , by Region USD Million (2023-2028)
  • Table 226. South America Antifungal Agents, by Country USD Million (2023-2028)
  • Table 227. South America Antifungal Agents, by Type USD Million (2023-2028)
  • Table 228. South America Antifungal Agents, by Application USD Million (2023-2028)
  • Table 229. South America Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 230. Brazil Antifungal Agents, by Type USD Million (2023-2028)
  • Table 231. Brazil Antifungal Agents, by Application USD Million (2023-2028)
  • Table 232. Brazil Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 233. Argentina Antifungal Agents, by Type USD Million (2023-2028)
  • Table 234. Argentina Antifungal Agents, by Application USD Million (2023-2028)
  • Table 235. Argentina Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 236. Rest of South America Antifungal Agents, by Type USD Million (2023-2028)
  • Table 237. Rest of South America Antifungal Agents, by Application USD Million (2023-2028)
  • Table 238. Rest of South America Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 239. Asia Pacific Antifungal Agents, by Country USD Million (2023-2028)
  • Table 240. Asia Pacific Antifungal Agents, by Type USD Million (2023-2028)
  • Table 241. Asia Pacific Antifungal Agents, by Application USD Million (2023-2028)
  • Table 242. Asia Pacific Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 243. China Antifungal Agents, by Type USD Million (2023-2028)
  • Table 244. China Antifungal Agents, by Application USD Million (2023-2028)
  • Table 245. China Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 246. Japan Antifungal Agents, by Type USD Million (2023-2028)
  • Table 247. Japan Antifungal Agents, by Application USD Million (2023-2028)
  • Table 248. Japan Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 249. India Antifungal Agents, by Type USD Million (2023-2028)
  • Table 250. India Antifungal Agents, by Application USD Million (2023-2028)
  • Table 251. India Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 252. South Korea Antifungal Agents, by Type USD Million (2023-2028)
  • Table 253. South Korea Antifungal Agents, by Application USD Million (2023-2028)
  • Table 254. South Korea Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 255. Taiwan Antifungal Agents, by Type USD Million (2023-2028)
  • Table 256. Taiwan Antifungal Agents, by Application USD Million (2023-2028)
  • Table 257. Taiwan Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 258. Australia Antifungal Agents, by Type USD Million (2023-2028)
  • Table 259. Australia Antifungal Agents, by Application USD Million (2023-2028)
  • Table 260. Australia Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 261. Rest of Asia-Pacific Antifungal Agents, by Type USD Million (2023-2028)
  • Table 262. Rest of Asia-Pacific Antifungal Agents, by Application USD Million (2023-2028)
  • Table 263. Rest of Asia-Pacific Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 264. Europe Antifungal Agents, by Country USD Million (2023-2028)
  • Table 265. Europe Antifungal Agents, by Type USD Million (2023-2028)
  • Table 266. Europe Antifungal Agents, by Application USD Million (2023-2028)
  • Table 267. Europe Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 268. Germany Antifungal Agents, by Type USD Million (2023-2028)
  • Table 269. Germany Antifungal Agents, by Application USD Million (2023-2028)
  • Table 270. Germany Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 271. France Antifungal Agents, by Type USD Million (2023-2028)
  • Table 272. France Antifungal Agents, by Application USD Million (2023-2028)
  • Table 273. France Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 274. Italy Antifungal Agents, by Type USD Million (2023-2028)
  • Table 275. Italy Antifungal Agents, by Application USD Million (2023-2028)
  • Table 276. Italy Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 277. United Kingdom Antifungal Agents, by Type USD Million (2023-2028)
  • Table 278. United Kingdom Antifungal Agents, by Application USD Million (2023-2028)
  • Table 279. United Kingdom Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 280. Netherlands Antifungal Agents, by Type USD Million (2023-2028)
  • Table 281. Netherlands Antifungal Agents, by Application USD Million (2023-2028)
  • Table 282. Netherlands Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 283. Rest of Europe Antifungal Agents, by Type USD Million (2023-2028)
  • Table 284. Rest of Europe Antifungal Agents, by Application USD Million (2023-2028)
  • Table 285. Rest of Europe Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 286. MEA Antifungal Agents, by Country USD Million (2023-2028)
  • Table 287. MEA Antifungal Agents, by Type USD Million (2023-2028)
  • Table 288. MEA Antifungal Agents, by Application USD Million (2023-2028)
  • Table 289. MEA Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 290. Middle East Antifungal Agents, by Type USD Million (2023-2028)
  • Table 291. Middle East Antifungal Agents, by Application USD Million (2023-2028)
  • Table 292. Middle East Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 293. Africa Antifungal Agents, by Type USD Million (2023-2028)
  • Table 294. Africa Antifungal Agents, by Application USD Million (2023-2028)
  • Table 295. Africa Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 296. North America Antifungal Agents, by Country USD Million (2023-2028)
  • Table 297. North America Antifungal Agents, by Type USD Million (2023-2028)
  • Table 298. North America Antifungal Agents, by Application USD Million (2023-2028)
  • Table 299. North America Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 300. United States Antifungal Agents, by Type USD Million (2023-2028)
  • Table 301. United States Antifungal Agents, by Application USD Million (2023-2028)
  • Table 302. United States Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 303. Canada Antifungal Agents, by Type USD Million (2023-2028)
  • Table 304. Canada Antifungal Agents, by Application USD Million (2023-2028)
  • Table 305. Canada Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 306. Mexico Antifungal Agents, by Type USD Million (2023-2028)
  • Table 307. Mexico Antifungal Agents, by Application USD Million (2023-2028)
  • Table 308. Mexico Antifungal Agents, by Indications USD Million (2023-2028)
  • Table 309. Antifungal Agents Sales: by Type(K Units)
  • Table 310. Antifungal Agents Sales Echinocandins , by Region K Units (2023-2028)
  • Table 311. Antifungal Agents Sales Azoles , by Region K Units (2023-2028)
  • Table 312. Antifungal Agents Sales Ployenes , by Region K Units (2023-2028)
  • Table 313. Antifungal Agents Sales Allylamines , by Region K Units (2023-2028)
  • Table 314. Antifungal Agents Sales Others , by Region K Units (2023-2028)
  • Table 315. Antifungal Agents Sales: by Application(K Units)
  • Table 316. Antifungal Agents Sales Powders , by Region K Units (2023-2028)
  • Table 317. Antifungal Agents Sales Ointments , by Region K Units (2023-2028)
  • Table 318. Antifungal Agents Sales Drugs , by Region K Units (2023-2028)
  • Table 319. Antifungal Agents Sales Pastes , by Region K Units (2023-2028)
  • Table 320. Antifungal Agents Sales: by Indications(K Units)
  • Table 321. Antifungal Agents Sales Aspergillosis , by Region K Units (2023-2028)
  • Table 322. Antifungal Agents Sales Dermatophytosis , by Region K Units (2023-2028)
  • Table 323. Antifungal Agents Sales Candidiasis , by Region K Units (2023-2028)
  • Table 324. Antifungal Agents Sales Others , by Region K Units (2023-2028)
  • Table 325. South America Antifungal Agents Sales, by Country K Units (2023-2028)
  • Table 326. South America Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 327. South America Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 328. South America Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 329. Brazil Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 330. Brazil Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 331. Brazil Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 332. Argentina Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 333. Argentina Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 334. Argentina Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 335. Rest of South America Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 336. Rest of South America Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 337. Rest of South America Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 338. Asia Pacific Antifungal Agents Sales, by Country K Units (2023-2028)
  • Table 339. Asia Pacific Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 340. Asia Pacific Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 341. Asia Pacific Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 342. China Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 343. China Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 344. China Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 345. Japan Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 346. Japan Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 347. Japan Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 348. India Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 349. India Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 350. India Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 351. South Korea Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 352. South Korea Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 353. South Korea Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 354. Taiwan Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 355. Taiwan Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 356. Taiwan Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 357. Australia Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 358. Australia Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 359. Australia Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 360. Rest of Asia-Pacific Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 361. Rest of Asia-Pacific Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 362. Rest of Asia-Pacific Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 363. Europe Antifungal Agents Sales, by Country K Units (2023-2028)
  • Table 364. Europe Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 365. Europe Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 366. Europe Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 367. Germany Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 368. Germany Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 369. Germany Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 370. France Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 371. France Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 372. France Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 373. Italy Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 374. Italy Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 375. Italy Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 376. United Kingdom Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 377. United Kingdom Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 378. United Kingdom Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 379. Netherlands Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 380. Netherlands Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 381. Netherlands Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 382. Rest of Europe Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 383. Rest of Europe Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 384. Rest of Europe Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 385. MEA Antifungal Agents Sales, by Country K Units (2023-2028)
  • Table 386. MEA Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 387. MEA Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 388. MEA Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 389. Middle East Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 390. Middle East Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 391. Middle East Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 392. Africa Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 393. Africa Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 394. Africa Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 395. North America Antifungal Agents Sales, by Country K Units (2023-2028)
  • Table 396. North America Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 397. North America Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 398. North America Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 399. United States Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 400. United States Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 401. United States Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 402. Canada Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 403. Canada Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 404. Canada Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 405. Mexico Antifungal Agents Sales, by Type K Units (2023-2028)
  • Table 406. Mexico Antifungal Agents Sales, by Application K Units (2023-2028)
  • Table 407. Mexico Antifungal Agents Sales, by Indications K Units (2023-2028)
  • Table 408. Antifungal Agents: by Type(USD/Units)
  • Table 409. Research Programs/Design for This Report
  • Table 410. Key Data Information from Secondary Sources
  • Table 411. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antifungal Agents: by Type USD Million (2017-2022)
  • Figure 5. Global Antifungal Agents: by Application USD Million (2017-2022)
  • Figure 6. Global Antifungal Agents: by Indications USD Million (2017-2022)
  • Figure 7. South America Antifungal Agents Share (%), by Country
  • Figure 8. Asia Pacific Antifungal Agents Share (%), by Country
  • Figure 9. Europe Antifungal Agents Share (%), by Country
  • Figure 10. MEA Antifungal Agents Share (%), by Country
  • Figure 11. North America Antifungal Agents Share (%), by Country
  • Figure 12. Global Antifungal Agents: by Type K Units (2017-2022)
  • Figure 13. Global Antifungal Agents: by Application K Units (2017-2022)
  • Figure 14. Global Antifungal Agents: by Indications K Units (2017-2022)
  • Figure 15. South America Antifungal Agents Share (%), by Country
  • Figure 16. Asia Pacific Antifungal Agents Share (%), by Country
  • Figure 17. Europe Antifungal Agents Share (%), by Country
  • Figure 18. MEA Antifungal Agents Share (%), by Country
  • Figure 19. North America Antifungal Agents Share (%), by Country
  • Figure 20. Global Antifungal Agents: by Type USD/Units (2017-2022)
  • Figure 21. Global Antifungal Agents share by Players 2022 (%)
  • Figure 22. Global Antifungal Agents share by Players (Top 3) 2022(%)
  • Figure 23. Global Antifungal Agents share by Players (Top 5) 2022(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 26. Abbott (United States) Revenue: by Geography 2022
  • Figure 27. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 29. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 31. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Merck & Co., Inc. (United States) Revenue: by Geography 2022
  • Figure 33. Sanofi-Aventis (France) Revenue, Net Income and Gross profit
  • Figure 34. Sanofi-Aventis (France) Revenue: by Geography 2022
  • Figure 35. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 37. Enzon Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Enzon Pharmaceuticals, Inc. (United States) Revenue: by Geography 2022
  • Figure 39. GlaxoSmithKline Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. GlaxoSmithKline Plc. (United Kingdom) Revenue: by Geography 2022
  • Figure 41. Astellas Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 42. Astellas Pharma (Japan) Revenue: by Geography 2022
  • Figure 43. Sigma-Aldrich (United States) Revenue, Net Income and Gross profit
  • Figure 44. Sigma-Aldrich (United States) Revenue: by Geography 2022
  • Figure 45. Global Antifungal Agents: by Type USD Million (2023-2028)
  • Figure 46. Global Antifungal Agents: by Application USD Million (2023-2028)
  • Figure 47. Global Antifungal Agents: by Indications USD Million (2023-2028)
  • Figure 48. South America Antifungal Agents Share (%), by Country
  • Figure 49. Asia Pacific Antifungal Agents Share (%), by Country
  • Figure 50. Europe Antifungal Agents Share (%), by Country
  • Figure 51. MEA Antifungal Agents Share (%), by Country
  • Figure 52. North America Antifungal Agents Share (%), by Country
  • Figure 53. Global Antifungal Agents: by Type K Units (2023-2028)
  • Figure 54. Global Antifungal Agents: by Application K Units (2023-2028)
  • Figure 55. Global Antifungal Agents: by Indications K Units (2023-2028)
  • Figure 56. South America Antifungal Agents Share (%), by Country
  • Figure 57. Asia Pacific Antifungal Agents Share (%), by Country
  • Figure 58. Europe Antifungal Agents Share (%), by Country
  • Figure 59. MEA Antifungal Agents Share (%), by Country
  • Figure 60. North America Antifungal Agents Share (%), by Country
  • Figure 61. Global Antifungal Agents: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Abbott (United States)
  • Pfizer Inc. (United States)
  • Novartis AG (Switzerland)
  • Merck & Co., Inc. (United States)
  • Sanofi-Aventis (France)
  • Bayer AG (Germany)
  • Enzon Pharmaceuticals, Inc. (United States)
  • GlaxoSmithKline Plc. (United Kingdom)
  • Astellas Pharma (Japan)
  • Sigma-Aldrich (United States)
Additional players considered in the study are as follows:
Kramer laboratories (United States) , Teva Pharmaceutical Industries (Israel) , Gilead Sciences (United States) , Astellas Pharma Inc. (Japan) , Enzon Pharmaceuticals (United States)
Select User Access Type

Key Highlights of Report


Jun 2023 201 Pages 94 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Antifungal Agents Quantitative research analysis
Global Antifungal Agents Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Antifungal Agents market are Abbott (United States), Pfizer Inc. (United States), Novartis AG (Switzerland), Merck & Co., Inc. (United States), Sanofi-Aventis (France), Bayer AG (Germany), Enzon Pharmaceuticals, Inc. (United States), GlaxoSmithKline Plc. (United Kingdom), Astellas Pharma (Japan) and Sigma-Aldrich (United States), to name a few.
is dominating the Antifungal Agents Market.
"Increased Resistance to Antifungal Drugs " is seen as one of the major challenges by many Industry Players of Antifungal Agents Market
The Antifungal Agents market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Antifungal Agents market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Antifungal Agents Report?

Have a Query? Click Here

Other Related Reports

Gabapentin Comprehensive Study by End Products (Capsule, Tablet, Solution, Suspension), Distribution Channel (Online Distribution Channel, Offline Distribution Channel), End Use (Adult (Epilepsy, Pos...
$ 3450
Drug Discovery Services Comprehensive Study by Type (Medicinal Chemistry Services, Biology Services, Drug Metabolism and Pharmacokinetics (DMPK), Market, by Drug Type, Small- molecule Drugs, Biologic...
$ 3750
Gene Editing Comprehensive Study by Type (Clustered Regularly Interspaced Short Palindromic Repeats, Transcription Activator-like Effector Nucleases (TALEN), Zinc-finger Nucleases (ZFNs), Homing Endo...
$ 3750
Sulfasalazine Tablets Comprehensive Study by Type (Enteric Sugar Coated Tablet, Film-Coated Tablet, Other), Application (Fever, Arthritis, Stomach pain, Diarrhea, Rectal bleeding, Others), Shape (Ova...
$ 3350
Biopharmaceutical Comprehensive Study by Type (Monoclonal Antibodies, Erythropoietin (EPO), Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferon...
$ 3750
Human Albumin Comprehensive Study by Type (Human Serum Albumin, Recombinant Serum Albumin), Application (Drug Delivery, Therapeutics, Culture Media, Vaccine Ingredient, Others), End-User (Pharmaceuti...
$ 3450